This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bioventus Surges 73% in Three Months: Time to Buy the Stock?
by Sundeep Ganoria
BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises.
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi
by Zacks Equity Research
Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi are included in this Analyst Blog.
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
by Zacks Equity Research
SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs
by Kinjel Shah
J&J tops third-quarter earnings and sales estimates. FDA approves new drugs of Pfizer, Roche and AbbVie.
J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?
by Kinjel Shah
JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.
ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike
by Sweta Killa
Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on the stock.
Stock Market News for Oct 16, 2024
by Zacks Equity Research
Wall Street ended lower on Tuesday as investors digested Mary Daly's remarks during a meeting at New York University, regarding interest rates.
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises
by Zacks Equity Research
Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance
by Zacks Equity Research
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Q3 Earnings Beats: C, GS, BAC, JNJ, WBA; Empire State Lower
by Mark Vickery
While Goldman Sachs (GS) and Citi (C) both impressed on earnings this morning, Walgreens (WBA) looks to bounce back.
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 9.01% and 1.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Q3 Earnings Results of U.S. Corporate Giants in Focus
by Zacks Equity Research
Q3 Earnings Results of U.S. Corporate Giants in Focus.
Bank Holiday Ahead of Busy Stock Trading Week
by Mark Vickery
Despite today's day off from econ metrics, we see a pretty busy week ahead.
Johnson & Johnson (JNJ) Stock Moves -0.09%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.51, denoting a -0.09% change from the preceding trading day.
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Intuitive Surgical Stock Declines 0.7% in a Month: Is It Losing Steam?
by Zacks Equity Research
ISRG stock has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. However, the stock has declined in the past month. Let's see if the trend might change.
Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Should Investors Consider High Yield Dividend Stocks?
by Derek Lewis
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But is high yield always the way to go?
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.